卵巢恶性肿瘤治疗中几个热点问题的循证医学研究
摘要
卵巢癌是妇科肿瘤中死亡率最高的恶性肿瘤。许多卵巢上皮性癌在诊断时就已经是晚期。虽然肿瘤细胞减灭术和规则化疗已经成为标准的卵巢癌治疗措施，卵巢癌总的5年生存率仍只有30%左右。本研究就卵巢癌治疗中初次手术腹膜后淋巴结清扫、晚期卵巢癌先期化疗、复发性卵巢癌再次手术和二线化疗热点问题进行临床及循证医学研究。临床数据来自广西肿瘤医院妇瘤科，同时对以上问题做循证医学研究。
影响卵巢恶性肿瘤预后的多因素分析
目的：探讨卵巢癌的预后因素。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的313例卵巢癌患者进行回顾性研究。用Kaplan-Meier法算生存率，差异性用Log-rank test进行比较。独立的预后因素用COX逐步回归模型确定。结果：多因素分析显示临床期别、残余灶、腹膜后淋巴结清扫和化疗疗程是重要的预后因素。
卵巢恶性肿瘤腹膜后淋巴结清扫临床价值的循证医学研究
目的：探讨卵巢恶性肿瘤腹膜后淋巴结清扫的临床价值。方法：对1985-2002年间在广西肿瘤医院妇瘤科治疗的361例卵巢上皮性癌患者进行回顾性研究。同时进行初次手术腹膜后淋巴结清扫的循证医学评价。结果：行淋巴清扫组和不行淋巴结清扫组的患者5年生存率分别为56.6%、48.2%，p<0.05。早期卵巢癌行腹膜后淋巴结清扫并不能提高生存率，P >0.05。晚期进行腹膜后淋巴结清扫的患者中，残余灶＜2cm和≥2cm的5年生存率分别为76.5%和38.5%，p<0.05。多因素分析显示：临床期别、残余灶、腹膜后淋巴清扫和化疗疗程是卵巢癌上皮性癌的独立预后因素。结论：虽然腹膜后淋巴结清扫可以改善卵巢癌患者生存率，但是建议有选择的进行。然而，循证医学证据显示腹膜后淋巴结清扫术有利于早期、晚期卵巢癌的预后。
卵巢恶性肿瘤先期化疗临床价值的循证医学研究
目的：研究先期化疗对晚期卵巢上皮性癌预后的影响。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的94例晚期卵巢上皮性癌患者进行回顾性研究，对其中68例未行先期化疗，直接进行传统的手术+辅助化疗和26例行先期化疗后手术的患者进行远期预后
的调查。同时进行先期化疗的循证医学研究。结果：94例晚期卵巢上皮性癌中，行先期化疗组和未行先期化疗组的5年生存率分别是21.6%和21.3%，没有统计学上差异，p>0.05。但是先期化疗组中，术后残余灶<2cm预后好于残余灶≥2cm的，P<0.05。多因素分析显示先期化疗不是晚期卵巢上皮性癌的独立预后因素。结论：先期化疗组中术后残余灶<2cm的预后好于残余灶≥2cm。循证医学证据表明证据还不足以充分说明先期化疗对卵巢癌术后的影响，其原因是与存在发表的偏倚和方法学质量低下的问题有关。
复发性卵巢癌再次手术临床价值的循证医学研究
目的：评价复发性卵巢上皮性癌再次手术的价值。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的43例复发性卵巢上皮性癌患者进行回顾性研究，同时进行循证医学研究。结果：43例晚期卵巢上皮性癌中行再次手术者和行二线化疗者的生存率没有统计学上差异，p>0.05。循证医学证据表明：再次手术对于铂类敏感、局限性复发的患者有意义。结论：再次手术对于复发性卵巢上皮性癌远期的预后仍不能定论。因为随机对照试验是不人道的。为了改善复发性卵巢上皮性癌的预后和提高生存率，最佳的挽救治疗方法仍需要进一步研究，包括选择最佳的时机和方式完成再次肿瘤细胞减灭术。
复发性卵巢癌二线化疗临床价值的循证医学研究
目的：评价复发性卵巢上皮性癌二线化疗的价值。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的25例复发性卵巢上皮性癌患者进行回顾性研究，同时进行循证医学研究。结果：25例复发性卵巢上皮性癌二线化疗预后与复发时间相关。二线化疗方案的选择及预后与是否铂类化疗敏感有关，应该根据累积毒性和临床表现进行个性化治疗。紫杉醇和卡铂/顺铂的方案是目前铂类敏感首选联合化疗方案，但是总的生存率仍不高。循证医学证据表明：铂类敏感型复发性卵巢上皮癌首选铂类化疗效果好。结论：复发性卵巢上皮性癌二线化疗应遵循个性化原则。为了改善复发性卵巢上皮性癌的预后和提高生存率，最佳的挽救治疗方法仍需要进一步研究，包括新的二线化疗药物的开发和新的联合治疗方法。
Ovarian cancer is the most common cause of female cancer mortality in women. Most patients with epithelial ovarian carcinoma present with advanced disease at the time of diagnosis. Although primary cytoreductive surgery or debulking procedure followed by systemic chemotherapy is the standard treatment protocol used in the management of ovarian cancer, the overall five-years survival is only about 30%. This study is to evaluate several “hotspot” of treatments for ovarian carcinoma, such as retroperitoneal lymphadenectomy in first cytoreductive surgery, neoadjuvant chemotherapy in patients with advanced epithelial ovarian carcinoma, secondary cytoreductive surgery and second-line chemotherapy in patients with recurrent epithelial ovarian carcinoma. It comprises data on ovarian cancer from the Department of female tumor of Guangxi Tumor Hospital and a large number of studies in ovarian cancer have been reviewed following the standard of evidenced-based medicine
Analysis prognostic factors of ovarian cancer
OBJECTIVE: The purpose of this study was to determine prognostic factors that have an impact on overall survival. METHODS: A retrospective review was performed of 313 patients treated between 1985 and 1998 at the Department of female tumor of Guangxi Tumor Hospital. Survival was calculated by Kaplan-Meier method and comparison was performed using Log-rank test. Independent prognostic factors were identified by the COX proportional hazards regression model. RESULTS: Multivariate analysis showed that stage, the size of residual tumor, retroperitoneal lymphadenectomy and the number of courses of chemotherapy were the most important prognostic factors.
Evidence-based research on clinical value of retroperitoneal
lymphadenectomy for ovarian cancer
OBJECTIVE: To explore the clinical value of retroperitoneal lymphadenectomy for ovarian cancer. METHODS: A retrospective review was performed of 361 patients treated between 1985 and 2002 at the Department of female tumor of Guangxi Tumor Hospital. On the other hand, a large number of studies on retroperitoneal lymphadenectomy in first cytoreductive surgery have
been reviewed. RESULTS: The overall 5-year survival was 56.6% and 48.2% for patients who did and did not undergo lymphadenectomy, respectively (P < 0.05). But the survival rate could not be improved through retroperitoneal lymphadenectomy in the patients with early stage (P > 0.05). Among patients with advanced stage who undergo lymphadenectomy , 5-year survival was 76.5% and 38.5% for patients whose size of residual tumor < 2 cm and >r =2cm, respectively (P < 0.05). Multivariate analysis showed that stage, residual tumor, retroperitoneal lymphadenectomy and the number of courses of chemotherapy is the prognostic factors in patients with epithelial ovarian cancer. CONCLUSIONS: Although retroperitoneal lymphadenectomy could improve the survival rate, it should be carried out selectively. However, there is evidence-based result showed that retroperitoneal lymphadenectomy could improve survival rate to a patient with early stage and advanced stage carcinoma.
Evidence-based research on clinical value of neoadjuvant chemotherapy for ovarian cancer
OBJECTIVE : The purpose of this study was to assess the survival benefit of neoadjuvant chemotherapy (NAC) in patients with FIGO stage Ⅲ or IV epithelial ovarian cancer. METHODS: In patients treated for stage Ⅲ or IV ovarian epithelial malignancies at the Department of female tumor of Guangxi Tumor Hospital between 1985 and 1998, 94 patients had a diagnosis of advanced ovarian carcinoma. For this group, the long-term outcome was compared between 68 patients receiving conventional adjuvant chemotherapy following standard surgery and 26 patients treated with NAC followed by a cytoreductive surgery. On the other hand, a large number of studies on neoadjuvant chemotherapy in stage Ⅲ or IV epithelial ovarian cancer have been reviewed. RESULTS: In a total of 94 patients with histologic types of epithelial ovarian malignancy, the overall 5-year survival was 21.6% a
影响卵巢恶性肿瘤预后的多因素分析
目的：探讨卵巢癌的预后因素。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的313例卵巢癌患者进行回顾性研究。用Kaplan-Meier法算生存率，差异性用Log-rank test进行比较。独立的预后因素用COX逐步回归模型确定。结果：多因素分析显示临床期别、残余灶、腹膜后淋巴结清扫和化疗疗程是重要的预后因素。
卵巢恶性肿瘤腹膜后淋巴结清扫临床价值的循证医学研究
目的：探讨卵巢恶性肿瘤腹膜后淋巴结清扫的临床价值。方法：对1985-2002年间在广西肿瘤医院妇瘤科治疗的361例卵巢上皮性癌患者进行回顾性研究。同时进行初次手术腹膜后淋巴结清扫的循证医学评价。结果：行淋巴清扫组和不行淋巴结清扫组的患者5年生存率分别为56.6%、48.2%，p<0.05。早期卵巢癌行腹膜后淋巴结清扫并不能提高生存率，P >0.05。晚期进行腹膜后淋巴结清扫的患者中，残余灶＜2cm和≥2cm的5年生存率分别为76.5%和38.5%，p<0.05。多因素分析显示：临床期别、残余灶、腹膜后淋巴清扫和化疗疗程是卵巢癌上皮性癌的独立预后因素。结论：虽然腹膜后淋巴结清扫可以改善卵巢癌患者生存率，但是建议有选择的进行。然而，循证医学证据显示腹膜后淋巴结清扫术有利于早期、晚期卵巢癌的预后。
卵巢恶性肿瘤先期化疗临床价值的循证医学研究
目的：研究先期化疗对晚期卵巢上皮性癌预后的影响。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的94例晚期卵巢上皮性癌患者进行回顾性研究，对其中68例未行先期化疗，直接进行传统的手术+辅助化疗和26例行先期化疗后手术的患者进行远期预后
的调查。同时进行先期化疗的循证医学研究。结果：94例晚期卵巢上皮性癌中，行先期化疗组和未行先期化疗组的5年生存率分别是21.6%和21.3%，没有统计学上差异，p>0.05。但是先期化疗组中，术后残余灶<2cm预后好于残余灶≥2cm的，P<0.05。多因素分析显示先期化疗不是晚期卵巢上皮性癌的独立预后因素。结论：先期化疗组中术后残余灶<2cm的预后好于残余灶≥2cm。循证医学证据表明证据还不足以充分说明先期化疗对卵巢癌术后的影响，其原因是与存在发表的偏倚和方法学质量低下的问题有关。
复发性卵巢癌再次手术临床价值的循证医学研究
目的：评价复发性卵巢上皮性癌再次手术的价值。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的43例复发性卵巢上皮性癌患者进行回顾性研究，同时进行循证医学研究。结果：43例晚期卵巢上皮性癌中行再次手术者和行二线化疗者的生存率没有统计学上差异，p>0.05。循证医学证据表明：再次手术对于铂类敏感、局限性复发的患者有意义。结论：再次手术对于复发性卵巢上皮性癌远期的预后仍不能定论。因为随机对照试验是不人道的。为了改善复发性卵巢上皮性癌的预后和提高生存率，最佳的挽救治疗方法仍需要进一步研究，包括选择最佳的时机和方式完成再次肿瘤细胞减灭术。
复发性卵巢癌二线化疗临床价值的循证医学研究
目的：评价复发性卵巢上皮性癌二线化疗的价值。方法：对1985-1998年间在广西肿瘤医院妇瘤科治疗的25例复发性卵巢上皮性癌患者进行回顾性研究，同时进行循证医学研究。结果：25例复发性卵巢上皮性癌二线化疗预后与复发时间相关。二线化疗方案的选择及预后与是否铂类化疗敏感有关，应该根据累积毒性和临床表现进行个性化治疗。紫杉醇和卡铂/顺铂的方案是目前铂类敏感首选联合化疗方案，但是总的生存率仍不高。循证医学证据表明：铂类敏感型复发性卵巢上皮癌首选铂类化疗效果好。结论：复发性卵巢上皮性癌二线化疗应遵循个性化原则。为了改善复发性卵巢上皮性癌的预后和提高生存率，最佳的挽救治疗方法仍需要进一步研究，包括新的二线化疗药物的开发和新的联合治疗方法。
Ovarian cancer is the most common cause of female cancer mortality in women. Most patients with epithelial ovarian carcinoma present with advanced disease at the time of diagnosis. Although primary cytoreductive surgery or debulking procedure followed by systemic chemotherapy is the standard treatment protocol used in the management of ovarian cancer, the overall five-years survival is only about 30%. This study is to evaluate several “hotspot” of treatments for ovarian carcinoma, such as retroperitoneal lymphadenectomy in first cytoreductive surgery, neoadjuvant chemotherapy in patients with advanced epithelial ovarian carcinoma, secondary cytoreductive surgery and second-line chemotherapy in patients with recurrent epithelial ovarian carcinoma. It comprises data on ovarian cancer from the Department of female tumor of Guangxi Tumor Hospital and a large number of studies in ovarian cancer have been reviewed following the standard of evidenced-based medicine
Analysis prognostic factors of ovarian cancer
OBJECTIVE: The purpose of this study was to determine prognostic factors that have an impact on overall survival. METHODS: A retrospective review was performed of 313 patients treated between 1985 and 1998 at the Department of female tumor of Guangxi Tumor Hospital. Survival was calculated by Kaplan-Meier method and comparison was performed using Log-rank test. Independent prognostic factors were identified by the COX proportional hazards regression model. RESULTS: Multivariate analysis showed that stage, the size of residual tumor, retroperitoneal lymphadenectomy and the number of courses of chemotherapy were the most important prognostic factors.
Evidence-based research on clinical value of retroperitoneal
lymphadenectomy for ovarian cancer
OBJECTIVE: To explore the clinical value of retroperitoneal lymphadenectomy for ovarian cancer. METHODS: A retrospective review was performed of 361 patients treated between 1985 and 2002 at the Department of female tumor of Guangxi Tumor Hospital. On the other hand, a large number of studies on retroperitoneal lymphadenectomy in first cytoreductive surgery have
been reviewed. RESULTS: The overall 5-year survival was 56.6% and 48.2% for patients who did and did not undergo lymphadenectomy, respectively (P < 0.05). But the survival rate could not be improved through retroperitoneal lymphadenectomy in the patients with early stage (P > 0.05). Among patients with advanced stage who undergo lymphadenectomy , 5-year survival was 76.5% and 38.5% for patients whose size of residual tumor < 2 cm and >r =2cm, respectively (P < 0.05). Multivariate analysis showed that stage, residual tumor, retroperitoneal lymphadenectomy and the number of courses of chemotherapy is the prognostic factors in patients with epithelial ovarian cancer. CONCLUSIONS: Although retroperitoneal lymphadenectomy could improve the survival rate, it should be carried out selectively. However, there is evidence-based result showed that retroperitoneal lymphadenectomy could improve survival rate to a patient with early stage and advanced stage carcinoma.
Evidence-based research on clinical value of neoadjuvant chemotherapy for ovarian cancer
OBJECTIVE : The purpose of this study was to assess the survival benefit of neoadjuvant chemotherapy (NAC) in patients with FIGO stage Ⅲ or IV epithelial ovarian cancer. METHODS: In patients treated for stage Ⅲ or IV ovarian epithelial malignancies at the Department of female tumor of Guangxi Tumor Hospital between 1985 and 1998, 94 patients had a diagnosis of advanced ovarian carcinoma. For this group, the long-term outcome was compared between 68 patients receiving conventional adjuvant chemotherapy following standard surgery and 26 patients treated with NAC followed by a cytoreductive surgery. On the other hand, a large number of studies on neoadjuvant chemotherapy in stage Ⅲ or IV epithelial ovarian cancer have been reviewed. RESULTS: In a total of 94 patients with histologic types of epithelial ovarian malignancy, the overall 5-year survival was 21.6% a
引文
林仲秋，石已复，Ngan HYS.卵巢癌FIGO分期.FIGO妇科肿瘤委员会IGCS指南委员会妇科恶性肿瘤分期及临床实践指南.第2版.广州:广东妇科肿瘤学组出版，2004,57-58
Cynthia DO,Rosemary DC,Sharan LC,et al.Survival of California women with epithelial ovarian cancer,1994-1996:a population-based study.Gynecol Oncol,2003,91:608-615
3 沈铿，郎景和.妇科肿瘤面临的问题和挑战.第一版.北京：人民卫生出版社,2002,89
4 Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol, 2003, 21(6):1180-1189
Hauptmann S, Denkert C, Koch I, et al. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol ,2002 ,33(6):632-641
Bichel P.A new histological grading index in ovarian carcinoma. Int J Gynecol PATHOL,1989,8:147
Vinokurov VL, Irzhanov SI, Zel'dovich DR, et al. Patterns in the metastasis of malignant ovarian tumors based on autopsy data .Vopr Onkol,1985,31(12):62-69
Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev, 2003 ,22(4):465-472
Terauchi F, Tanabe K, Tenmyo M, et al. Clinical study on total omentumectomy for ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi, 1995 ,47(1):14-18
Sakai K, Kamura T, Hirakawa T,et al. Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer. Gynecol Oncol, 1997 ,65(1):164-8
Vinokurov VL, Kolosov AE, Nechaeva ID，et al. Characteristics of the metastasis of endometrioid cancer of the ovaries into the greater omentum. Vopr Onkol, 1979,25(3):20-24
Vinokurov VL, Kolosov AE. metastasis to the greater omentum Vopr Onkol, 1980,26(2):30-34
Funt SA, Hricak H. Ovarian Malignancies. Topics in Magnetic Resonance Imaging. Magnetic Resonance Imaging in Gynecologic Disease, 2003,14(4):329-337
Wu PC, Lang JH, Huang TL, et al. Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer. Clin Obstet Gynecol,1989,3:143
Di Te F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at
the end of the second millennium. Int J gynecol Cancer,2000,10(6):435-442
Brughardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaotic lymph node involvement in ovarian cancer. Gynecol Oncol,1997,40(2):103-106
Di Re F,Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer. prognostic significance of node metastases. Gynecol Oncol,1996,62:360-365
Parazzini F, Valsecchi G, Bolis G, et al. Pelvic and paraotic lymph nodal status in advanced ovarian cancer and survival .Gynecol Oncol,1999,74(1):7-11
Cormio G, Rossi C, Cazzolla A,et al. Distant metastases in ovarian carcinoma.Int J Gynecol Cancer.,2003 ,13(2):125-129
Muggia FM, Braley PS, Brady MF, et al. Phase Ⅲ randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or IV ovarian cancer: A gynecologic oncology group study.J Clin Oncol 2000,18(1):106-115
du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst,2003,95(17):1320-1329
吴令英，张蓉，章文华.紫杉醇联合铂类周疗与月疗治疗卵巢上皮性前瞻性研究.肿瘤学杂志,2002，8(4):190
23 Sehouli J, Stengel D, Elling D, et al. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.Gynecol Oncol, 2002 ,85(2):321-326
24 Seidman AD, Hudis CA, Albanel J, et al. Dose—dense therapy with weekly 1—hour paclitaxel infusions in the treatment of metastatic breast cancer .J Clin Oncol,1998,16:3353—3361
25 Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol, 2003 ,90(3 Pt 2):8-15
26 Copeland LJ, Bookman M, Trimble E,et al. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol, 2003 ,90(2 Pt 2):1-7
27 Bristow TE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol,2002,20:1248-1259
28 Hogberg T; Glimelius B; Nygren P,et al.A systematic overview of chemotherapy effects in ovarian cancer.Acta Oncol, 2001,40(2-3):340-360
29 Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003,3(7):502-516
Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol, 2003 , 90(3 Pt 2):39-44
Hogdall EV, Christensen L, Kjaer SK,et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer, 2003 , 98(1):66-73
Tanner B, Kreutz E, Weikel W,et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol, 1996 ,62(2):268-77
33 Rose SL, Goodheart MJ, DeYoung BR, et al. p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res, 2003, 9(3):1028-1032
34 Scambia G, Masciullo V, Benedetti Panici P, et al.Prognostic significance of ras/p21 alterations in human ovarian cancer. Br J Cancer, 1997,75(10):1547-1553
35 Schuyer M, van der Burg ME, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.Br J Cancer, 2001 ,85(9):1359-1367
36 Kupryjanczyk J, Szymanska T, Madry R, et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer, 2003,88(6):848-854
37 Morita K, Ono Y, Fukui H, et al. Incidence of p53 and K-ras alteration in ovarian mucinous and serous tumors. Pathol Int,2000,50(3):219-223
38 Havrilesky L, Darcy M, Hamdan H, et al.Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol, 2003, 21(20):3814-3825
39 Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat, 2003,21(3):285-291
Gadducci A, Cosio S, Muraca S, et al. Molecular mechanisms of apoptosis and
chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol, 2002,23(5):390-396
41 Okada K,Urano T,Goi T,et al.Isolation of human nm23 genomens and analysis of loss of heterozygosity in primary colorectal carcinomas using a specifi genomic probe,Cancer Res,1994,54:3879
42 Galani E, Sgouros J, Petropoulou C,et al. Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res, 2002 ,22(4):2275-2280
43 Tomic S, Ilic Forko J, Babic D,et al. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Croat Med J, 2003 , 44(4):429-434
44 Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol, 2000 ,19(1):3-10
45 Tanake K. Molecular biology of ovarian cancer Gan To Kagaku Ryoho, 1999, 26(14): 2162-2167
46 Reedy M, Gallion H, Fowler JM, et al.Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol, 2002 ,85(2):255-259
47 O'Rourke J, Mahon SM. A comprehensive look at the early detection of ovarian cancer. Clin J Oncol Nurs, 2003 ,7(1):41-47
48 Ivanov S, Ivanov S. Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factorAkush Ginekol (Sofiia),2003,42(3):16-19
49 Nyvang GB,Mogensen O,Bichel P,et al.Combined prognostic importance of CA125, histopathologic grade and DNA-index in advanced ovarian cancer.Eur J Gynaecol Oncol,2000,21(6):569-572
50 Zakrzewska I. CA-125 antigen. Postepy Hig Med Dosw,2002,56(1):29-38
51 Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist, 2002,7 Suppl 5:20-28
52 Yancopoulos GD, Davis S, Gale NW, et al. Vascular specific growth factors and blood vessel formation. Nature ,2000,407:242–248
53 Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol, 1999,237:41–57
54 Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest, 1996,74:1105–1115
55 Alvarez AA, Krigman HR, Whitaker RS, et al.The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res, 1999, 5:587-591
56 Wong Te Fong LF, Gammell SJ, Bamberger ES, et al. Quantification of VEGF-A and PD-ECGF/TP in normal, benign and malignant ovarian lesions. Rev Oncol 2002,4(suppl 1):122
57 Siddiqui GK, Wong Te Fong LF, Rolfe KJ, et al. The expression of VEGF-A in metastatic epithelian ovarian cancer is of prognostic significance. Br J Obstet Gynaecol, 2001,108:549
58 Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol, 2002 ,55(6):348-359
59 Suzuki M, Kobayashi H, Ohwada M, et al. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors in the ovary.Gynecol Oncol,1998,68:35-37
60 Toy EP, Chambers JT, Kacinski BM,et al. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol, 2001, 80(2):194-200
61 Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res, 2003, 63(6):1413-1419
62 Le T, Adolph A, Krepart GV,et al.The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.Gynecol Oncol, 2002,85(2):351-355
63 Rubin SC, Markman M. Surgical staging of ovarian cancer. Bristol-Myers Oncology Division Medical Education Services. Bristol-Myers Squibb Company, Princeton, New Jersey, 1992
64 Takec I. Role of appendectomy in predicting lymph node metastases in patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 2000,88(2):159-163
65 Bese T,Kosebay D,Kaleli S,etal.Appendectomy in the surgical staging of ovarian carcinoma. Int J Gynaecol Obstet,1996,53(3):249-252
66 Fawzi HW, Robertshaw JK, Bolger BS, et al.Role of appendicectomy in the surgical management of ovarian cancer.Eur J Gynaecol Oncol, 1997,18(1):34-35
67 Kecmanovic DM, Pavlov MJ, Kovacevic PA, et al. Cytoreductive surgery for ovarian cancer. Eur J Surg Oncol,2003 ,29(4):315-320
68 Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother, 2001 ,2(1):109-124
69 Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium. Int J Gynecol Cancer, 2000 ,10(6):435-442
70 Yokoyama Y,Sakamoto T,Sato S,etal.Evaluation of cytoruductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.Eur J Gynaecol Oncol,1999,20(5-6):132-366
Faught W, Le T, Fung Kee Fung M, et al. Early ovarian cancer: what is the staging impact of retroperitoneal node sampling? J Obstet Gynaecol Can，2003 , 25(1):18-21
Burghardt E,Pickel H,Lahousen M,et al.Pelvic lymphadenectomy in operative treatment of ovarian cancer.Am J Obstet Gynecol,1986,155(2):315-319
Kikkawa F,Ishikawa H,Tamakoshi K,et al.Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer.J Surg Oncol,1995,60(4):227-231
Saygili U, Guclu S, Uslu T,et al. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage Ⅲ ovarian carcinoma? A DEGOG* Study. J Surg Oncol, 2002 ,81(3):132-137
Kigawa J,Minagawa Y,Itamochi H,et al.Retroperitoneal lymphadenectomy,including the para-aortic nodes in patients in patients with stage Ⅲ ovarian cancer.Am J Clin Oncol,1994,17(3):230-233
76 Morice P, Camatte S, Wickart-Poque F,et al. Conservative management of malignant and borderline ovarian tumor.Bull Cancer,2002 , 89(12):1019-1026
77 Morice P,Wicart-Poque F,Rey A,et al.Results of conservative treatment in epithelial ovarian carcinoma.Cancer,2001,92(9):2412-2418
Plante M.Fertility preservation in the management of gynecologic cancers .Curr Opin Oncol,2000,12:495-497
Zanetta G,Chiari S,Rota S,et al.Conservative surgery for stage I ovarian canrcinoma in women of childberaring age.Br J Obstet Gynaecal,1997,104(9):1030-1035
80 Morice P, Camatte S, Wicart-Poque F ,et al.Results of conservative management of epithelial malignant and borderline ovarian tumours.Hum Reprod Update.,2003,9(2):185-192
81 Ayhan A, Celik H, Taskiran C, et al.Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.Eur J Gynaecol Oncol, 2003,24(3-4):223-232
82 Suzuki M , Tsukagoshi S, Ohwada M et al.A patient with brain metastasis from ovarian cancer who showed complete remission after multidisciplinary treatment. Gynecol Oncol ,1999,74(3):483-486
83 Onnis A ,Marchetti M, Padovan P et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol,1996,17:393-396
84 Munkarrah AR, Hallum AV, Morris M et al.Prognostic significance of residual disease in patients with stage Ⅳ epithelial ovarithelial ovarian cancer. Gynecol Oncol, 1997,64:13-7
85 Dauplat J, Bouedec G, Pomel C,et al.Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol ,2000,19(1):42-48
86 Tingulstad S, Skjeldestad FE, Hagen B.The effect of centralization of primary surgery on survival in ovarian cancer patients.Obstet Gynecol, 2003 ,102(3):499-505
87 Hamid D,Rohr S,Baldauf JJ,et al.Interest in intestinal resection for treatment of advanced ovarian cancer.Ann Chir,2002,127(1):40-47
88 Balbi GC,Compagna R,Musone R, et al.Cytoreductive surgery in patients with stage IV ovarian carcinoma.Mineva Gynecol,2001, 53[Suppl 1]:105-109
89 Todo Y, Sakuragi N, Oikawa M, et al. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.Int J Clin Oncol, 2003 ,8(2):90-96
90 Friedman TL, Eisenkop SM, Wang HJ. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol,1997,67(1):88-94
91 Baker VV. Treatment Options for Ovarian Cancer. Clinical Obstetrics & Gynecology, 2001 ,44(3):522-530
92 Ott HW, Illmensee K, Zeimet A, et al.The evaluation of the second-look operation of patients with ovarian carcinoma and tubal carcinoma by means of a retrospective comparison study.Gynakol Geburtshilfliche Rundsch, 2002,42(4):217-224
93 Eisenkop SM,Friedman RL,Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer,2000,88(1):144-153
94 Munkarah A, Levenback C, Wolf JK, et al.Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol,2001,81(2):237-241
95 Federica B, Monica C, Nicola R, et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res, 1999, 5: 1837-1842
96 Kazuya K, Masashi T, Tomoyuki K, et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res ,1999, 5: 2526-2531
97 Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist, 2002,7(5):20-28
98 Salom E, Almeida Z, Mirhashemi R. Management of recurrent ovarian cancer: evidence-based decisions. Current Opinion in Oncology, 2002,14(5):519-527
99 Bristow RE. Surgical standards in the management of ovarian cancer. Current Opinion in Oncology, 2000, 12(5):474-480
100 Udarah A, Levenback C, Wolf J, et al. Secondary cytoreductive surgery for intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol, 2001, 81:237–241
101 kuhn W, Schmalfeldt B, Pache L, et al. Disease-adapted relapse therapy for ovarian cancer: results of a prospective study. Int J Oncol, 1998, 13:57–63
102 Mundarah A, Levenback C, Wolf J, et al. Secondary cytoreductive surgery for intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol, 2001, 81:237–241
103 Eisenkop SM, Friedman RL, Spirtos NM.The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer, 2000, 88(1):144-153
104 Tay EH, Grant PT, Gebski V, et al.Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Obstet Gynecol,2002 , 99(6):1008-1113
105 Gadduci S,Iacconi P,Cosio S,et l.Complete salvage surgical cytoreduction improves further survivial of patients with late recurrent ovarian cancer.Gynecol oncol,2000,79:344-349
106 Kuhn W,Schmalfeldt B,Pache L,et al.Disease-adapted relapse therapy for ovarian cancer:results of a prospective study .Int J Oncol,1998,13(1):57-63
107 McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with
paclitaxel and cisplatin in patients with stage Ⅲ and stage IV ovarian cancer. N Engl J Med ,1996, 334:1–6
108 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase Ⅲ randomized trial in patients with suboptimal stage Ⅲ/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol ,1996,23(12):40-47
109 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage Ⅲ and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol, 1997,24(2):S2-13-S2-16
110 Schink JC. Current initial therapy of stage Ⅲ and IV ovarian cancer: challenges for managed care. Semin Oncol 1999, 26:2–7
111 Piccart MJ,Bertelsen K,James K,et al.Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer :three-year results.J Natl Cancer Inst,2000,92(9):699-708
112 Fleming GF, Toth BJ,Baker SD,et al.Phase I trial of paclitaxel and etoposide for recurrent ovarian cancer: a Gynecologic Oncology GroupStudy.Am J Clin,2000,23(6):609-613
113 Bristow RE, Tomacruz RS, Amstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002, 20:1248-1259
114 Pecorelli S, Odicino F, Favalli G. Ovarian cancer: best timing and applications of debulking surgery. Ann Oncol ,2000, 11 (Suppl 3):141-144
115 Amikura T, Aoki Y, Kase H,et al. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy.Int J Clin Oncol, 2002 , 7(1):45-50
116 Eltabbakh GH,Piver MS,Hempling RE,et al.Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovrian cancer.Gynecol Oncol,1998,71(2):190-195
117 Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. Cancer ,2001, 91:2239-2334
118 Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage ⅢC ovarian carcinoma. Cancer, 2001, 92:2585-2591
119 Eisenkop SM, Spirtos NM, Friedman RL. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol ,1999, 74: 311-313
121 Kayikciog Lu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer, 2001, 11:466-470
122 Markman M: Intraperitoneal therapy of ovarian cancer. Semin Oncol ,1998, 25:356–360
123 Friberg G, Fleming G.Intraperitoneal chemotherapy for ovarian cancer. Curr Oncol Rep, 2003,5(6):447-453
124 Rossi CR, Mocellin S, Pilati P, et al.Pharmacokinetics of intraperitoneal cisplatin and doxorubicin.Surg Oncol Clin N Am, 2003 ,12(3):781-794
117 Gurkan Zorlu C, Eylem Seker Ari P. Hyperthermia in gynecologic cancers.Eur J Gynaecol Oncol, 2003,24(3-4):282-286
125 Fujiwara K, Sakuragi N, Suzuki S, First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.Gynecol Oncol, 2003 ,90(3):637-643
126 Makhija, Sharmila AS, Paul BB, et al. Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Current Opinion in Obstetrics & Gynecology, 1999,11(1):23-27
127 Khabele D, Runowicz CD, Fields AL, Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies.Gynecol Oncol, 2003 ,89(3):420-423
128 Breidenbach M, Rein DT , Mallmann Peter ,et al. Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anti-Cancer Drugs, 2002, 13(2):173-176
129 Piccart M. J, Lamb H, Vermorken J B.. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Annals of Oncology, 2001,12(9):1195-1203
130 Dancey J, Zee B, Osoba D, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer
Institute of Canada Clinical Trials Group. Qual Life Res, 1997, 6:151-158
131 Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol, 1999, 10 (Suppl 1): 87-92
132 Giaccone G. Clinical perspectives on platinum resistance. Drugs ,2000, 59 (Suppl 4): 9-17
133 Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist, 2000, 5: 26-35
134 Aravantinos G, Bafaloukos D, Fountzilas G, Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.Ann Oncol, 2003 ,14(7):1094-1199
135 Herzog TJ, Holloway RW, Stuart GC. Workshop: options for therapy in ovarian cancer.Gynecol Oncol, 2003 ,90(3 Pt 2): 45-50
136 Berek JS,Bertelsen K,du Bois A,et al.Advanced epithelial ovarian cancer:1998 consensus statements.Ann Oncol,1999,10(Suppl 1):87-92
137 Deppe G, Baumann P. Advances in ovarian cancer chemotherapy. Current Opinion in Oncology, 2000,12(5):481-491
138 Morris RT. Weekly topotecan in the management of ovarian cancer.Gynecol Oncol, 2003 ,90(3 Pt 2): 34-38
139 Miller DS, Blessing JA, Lentz SS, Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.Cancer, 2003 ，98(8):1664-1669
140 Fruscella E, Gallo D, Ferrandina G, Gemcitabine: current role and future options in the treatment of ovarian cancer.Crit Rev Oncol Hematol,2003 ,48(1):81-88
141 Rose PG, Blessing JA, Ball HG, et al.A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol, 2003,88(2):130-135
142 Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene–glycol coated liposomes. Cancer Res, 1994, 54:987–992
143 Tambaro R, Greggi S, Iaffaioli R,et al. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. Annals of Oncology, 2003 ,14(9):1406-1411
144 Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol ,2000,78:369–372
145 D'Agostino G, Ferrandina G, Ludovisi M, Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.Br J Cancer, 2003 ,89(7):1180-1184
146 Rose PG, Blessing JA, Mayer AR. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian cancer. A Gynecologic Oncology Group study. J Clin Oncol, 1998, 16: 405–10
147 Ostanin AA, Chernykh HR, Leplina OY, IL-2-Activated Killer Cells and Native Cytokines in Treatment of Patients with Advanced Cancer.Russ J Immunol, 1997 ,2(3-4):167-176
148 Lum LG,Lefever AV,Treisman JS,et al.Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial.J Immunother, 2001 ,24(5):408-419
149 Marme A, Strauss G, Bastert G,et al. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma.Int J Cancer, 2002 ,101(2):183-189
150 Melichar B, Savary CA, Patenia R, et al. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma.Int J Gynecol Cancer, 2003 ,13(4):435-443
151 Berek JS,Stonebraker B,Lentz SS,et al.Intraperitoneal alpha-interferon in residual ovarian carcinoma:a phase II gynecologic oncology group study .Gynecol Oncol,1999,75:10-14
152 Santin AD，Ioli GR，Hiserodt JC，et al．Development and charac＿terization of an IL－4－secreting human ovarian carcinoma cell line．Gynecol Oncol，1995，58：230
153 D＇Incan C，Sanches R，Kuiper M，et al．Gamma－interferon genetransfer as a therapeutic strategy for ovarian cancer．Adv Exp Med Biol，1998，451：349
154 Bernhard H, Salazar L, Schiffman K,et al. Vaccination against the HER-2/neu oncogenic protein.Endocr Relat Cancer, 2002,9(1):33-44
155 Linehan DC, Peoples GE, Hess DT, et al.In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. Surg Oncol, 1995,4:41-49
156 Brossart P. Dendritic cells in vaccination therapies of malignant diseases.Transfus Apheresis
Sci, 2002 ,27(2):183-186
157 Reinartz S,Boerner H,Koehler S,et al.Evaluation of immunological responses in patients with ovarian cancer the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report .Hybridom,1999,18:41-45
158 Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ,et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.Oncogene, 2003 ,22(3):370-380
159 Grove JI, Lovering AL, Guise C,et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.Cancer Res, 2003,63(17):5532-5537
160 Alvarez RD, Barnes MN, Gomez-Navarro J,et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.Clin Cancer Res, 2000,6(8):3081-3087
161 Wen SF, Mahavni V, Quijano E,et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.Cancer Gene Ther, 2003 ,10(3):224-238
162 Buller RE, Runnebaum IB, Karlan BY, et al.A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.Cancer Gene Ther,2002,9(7):553-566
163 Saga Y, Mizukami H, Takei Y,et al. Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression.Int J Oncol, 2003 ,23(4):1109-1113
164 Qian HN, Liu GZ, Cao SJ,et al. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes.Int J Gynecol Cancer, 2002 ,12(1):80-85
165 Schiedlmeier B, Schilz AJ, Kuhlcke K,et al. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice.Hum Gene Ther, 2002 ,13(2):233-242
166 Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer.Gan To Kagaku Ryoho, 2003 ,30(4):468-477
167 Kohno T, Mizukami H, Suzuki M,et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.Cancer Res, 2003 ,63(16):5091-5094
168 Mu J, Abe Y, Tsutsui T,et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Jpn J Cancer Res, 1996 ,87(9):963-971
169 Saul HM, Sedlacek TV, Heller PB,et al. Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer.J Am Osteopath Assoc, 1996 ,96(12):727-732
170 Condra KS, Mendenhall WM, Morgan LS,et al. Adjuvant 32P in the treatment of ovarian carcinoma.Radiat Oncol Investig, 1997,5(6):300-304
171 Einhorn N, Trope C, Ridderheim M,et al. A systematic overview of radiation therapy effects in ovarian cancer.Acta Oncol,2003,42(5-6):562-566
172 Firat S, Murray K, Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.Int J Radiat Oncol Biol Phys, 2003 ,57(1):201-207
173 Randall ME, Barrett RJ, Spirtos NM,et al. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys, 1996 ,34(1):139-147
174 Pickel H, Lahousen M, Petru, et al.Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer.Gynecol Oncol,1999,72(2):215-219
175 Hepp R, Baeza MR, Olfos P,et al. Adjuvant whole abdominal radiotherapy in epithelial cancer of the ovary.Int J Radiat Oncol Biol Phys, 2002, 53(2):360-365
176 Goldberg H, Stein ME, Steiner M,et al. Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up.Tumori, 2001 ,87(4):248-251
177 MacGibbon A, Bucci J, MacLeod C,et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma.Gynecol Oncol, 1999 ,75(1):62-67
178 Condra KS, Mendenhall WM, Morgan LS,et al. Condra KS, Mendenhall WM, Morgan LS, Marcus RB, Jr. Consolidative 32P after second-look laparotomy for ovarian carcinoma. Radiation Oncology Investigations, 1998;6(2): 97-102
179 Petera J, Spacek J, Odrazka K. Radiotherapy in the treatment of ovarian epithelial
carcinoma.Ceska Gynekol, 2003,68(4):264-269
180 Fujiwara K, Suzuki S, Yoden E,et al. Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.Int J Gynecol Cancer, 2002 ,12(3):250-256
181 Corn BW, Mehta MP, Buatti JM, et al. Stereotactic Irradiation: potential new treatment method for brain metastases resulting from ovarian cancer. Am J Clin Oncol, 1999,22(2):143-146
182 Fyles AW, Thomas GM, Pintilie M, et al. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II and Ⅲ ovarian cancer .Int J Radiat Oncol Biol Phys,1998,41(3):543-549
183 Quetin P, Marchal C, Hoffstetter S,et al. Tolerance and role of irradiation in the treatment of epithelial cancer of the ovary.Cancer Radiother, 1998,2(4):366-374
184 Wolf JK, Mullen J, Eifel PJ,et al. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary.Gynecol Oncol, 1999, 73(1):35-41
185 Sackett DL, Straus SE, Richardson WS, et al. Evidence-based medicine: How to practice and teach evidence-based medicine. London: Churchill Livingstone,2000 :1-19
186 Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst, 2003,95(17):1276-1299
187 Salom E, Almeida Z, Mirhashemi Rv. Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol,2002 ,14(5):519-527
188 David AG, David A. The U.S. Preventive services task force: putting evidence-based medicine to work. Clinical Obstet Gynecol,1998,41(2):332-342
189 Gray RE, Chart P, Carroll JC, et al. Family physicians’ perspectives on ovarian cancer. Cancer Prev Control,1999,3(1):61-67
190 Lefebvre G, Allaire C, Jeffrey J. SOGC clinical guidelines.Hysterectomy. J Obstet Gynaecol Can,2002,24(1):37-61
191 Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.J Natl Cancer Inst, 2002,94:497-504
192 David MP.Hormone replacement therapy with continuous progestins was not associated with
an increased risk of ovarian cancer. Evidence-based Obstetrics and Gynecology,2002,4:150-151
193 Teede HJ. Hormone replacement therapy and the prevention of cardiovascular disease. Human Reproduction Update, 2002，8(3):201-215
194 Modan B, Hartge P, Hirsh-Yechezkel G,et al.Oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA1 mutation .N Engl J Mde,2001,345:235-240
195 Bengt G, Jonas B, Lars B, et al.The Swedish council on technology assessment in health care(SBU) systematic overview of chemotherapy effects in some major tumour types-summary and conclusion.Acta Oncol,2001,40:135-154
196 Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, Ⅲ, or IV epithelial ovarian cancer. Gynecol Oncol,2002, 85(1):71-80
197 Williams C, Collingwood M, Simera, et al. Short versus long duration infusions of paclitaxel for any adenocarcinoma(Cochrane Review). Oxford .Cochrane Library.Issue 2 .2003
198 Vermorken JB. Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer, 2001,11 suppl1:73-76
199 Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer (Cochrane Methodology Review). Oxford .Cochrane Library.Issue 4 .2003
200 Trope C ,Paulsen T ,baekelandt M ,et al. Controversies in surgical treatment of advanced ovarian cancer .Tidsskr Nor Laegeforen,2000,120(7):824-830
201 Cantu M, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.J Clin Oncol, 2002,20:1232-1237
202 Gordon AN, Fleagle JT,Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase Ⅲ study of pegylated liposmal doxorubicin versus topotecan. J Clin Oncol,2001,19(14):3312-3322
203 Willian CJ,Simera I.Tamoxifen for relapse of ovarian cancer(Cochran Review). Oxford. Cochrane Library.Issue 4 .2003
van T M, Furlan A, Bombardier C ,et al. the Editorial Board of the Cochrane Collaboration Back Review Group. Updated Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group. Spine, 2003 ,28(12):1290-1299
Clark TG, Stewart ME, Altman DG,et al.A prognostic model for ovarian cancer.Br J Cancer ,2001,85:944-952
Brun JL,Feyler A,Chene G,et al.Long term results and prognostic factors in patients with epithelial ovarian cancer.Gynecol Oncol,2000,78:21-27
Bristow TE,Tomacruz TS,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis.J Clin Oncol,2002,20:1248-1259
Scarabelli C, Gallo A, Franceschi S et al.Primary Cytoreductive surgery with rectosigmoid colon for patients with advanced epithelial ovarian carcinoma. Cancer ,2000,88(2):389-97
熊宙芳，王泽华，王世宣.卵巢上皮性癌的腹膜后淋巴结切除对预后的影响.中华妇产科杂志，2003，38(2):77
Poveda A.Ovarian cancer treatment: what is new. Int J Gynecol Cancer,2003,13 (Suppl 2):241-250
Yokoyama Y,Sakamoto T,Sato S,et al. Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.Eur J Gynaecol Oncol, 1999, 20(5-6):361-366
Allen DG, Coulter J. Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease.Aust NZJ Obstet Gynaecol ,1999 ,39(4):420-424
Tien Le, Allyson Adolph, G.V. Krepart, et al.The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.Gynecol Oncol,2002,85:351-355
王荣业.84例晚期卵巢上皮癌的综合治疗.浙江肿瘤.2000,6(2):75-77
熊宙芳，王泽华，王世宣.卵巢上皮性癌的腹膜后淋巴结切除对预后的影响.中华妇产 科杂志.2003，38（2）：77-80
Scott M.Eisenkop, Nick M.Spirtos, Richard L.Friedman, et al. Relative influences of tumor
volume before surgery and the advanced ovarian cancer:a prospective study.2003,90:390-396
Ho CM, Chien TY, Shih BY,et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol, 2003,88(3):394-399
Moher D, Dook DJ, Eastwood S,et al. Improving the quality of reports of Meta-analyses of randomized controlled trials: the QUOROM statement. The Lancer,1999, 354(27):1896-1900
Jadad AR, Moore RA, Carroll D,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996 ,17(1):1-12
Moher D，Pham B，Jones A， et al．Does quality of reports of randomised trials affect estimates of intervention efficacy reported in Metaanalyses［J］．Lancet ,1998, 352:609-613
Clarke M，Oxman AD，editors．Cochrane Reviewers Handbook 4.0; Section 6．In:The Cochrane Library［database on CDROM］．The Cochrane Collaboration．Oxford:Update Software;2000，issue 1
Schula KF，Chalmers I，Hayes R，Altman D．Empiricalevidence of bias［J］．JAMA,1995, 273（5）: 408-412
Vickers A，Goyal N，Harland R，Rees R．De certain countries preduce only positive results? A systematic review of controlled trials［J］．Control Clin Trials ,1998, 19:159-166
Egger M，Devey Smith G，Schneider M，et al．Bias in Meta-analysis detected by a simple graphical test［J］．BwJ ,1997, 315:629-634
郎景和.I期卵巢癌的淋巴结转移，中华妇产科杂志，1992,27:338
Morice P, Joulie F, Rey A,et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol, 2004;25(2):169-174
Fabio FP，Giorgio B, Paolo G,et al. Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival.Gynecol Oncol, 1999,74:7-11
Baiocchi G, Grosso G, di Re E, et al. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Gynecol Oncol, 1998,69:151
Gadducci A, Sartori E, Maggino T ,et al. analysis of failures after negative second-look in patients with advanced ovarian cancer; an Italian multicenter study. Gynecol Oncol, 1998, 68:150
230 Peter E.Schwartz.Neoadjuvant chemotherapy for the management of ovarian cancer.Best Practice & Research Clinical Obstetrics and Gynaecology,2002,16(4):585-596
231孙延慰，祝亚平，李双弟，等.上皮性卵巢癌的综合治疗及疗效分析.上海医学.2001,24(8):487-489
232 Kayikciog Lu F,Kose MF,Boran N,et al.Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma.Int J Gynecol Cancer,2001,11:466-470
233 Fanfani F, Ferrandina G, Corrado G,et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage Ⅲc ovarian cancer patients. Oncology, 2003,65(4):316-322
234 Morice P, Brehier-Ollive D, Rey A,et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol, 2003,14(1):74-77
235 Kuhn W, Rutke S, Spather K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage Ⅲc ovarian carcinoma. Cancer, 2001, 92:2585
236 Ansquer Y, Leblanc E, Clough K, et al.Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer, 2001(81):2329-2334
237 Schwartz PE, Rutherford TJ, Chambers JT,et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol,1999,72:93-99
238 Vergote I,Dewever I,Tjalma W,et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology ,1998(71):431-436
239 Zang RY, Li ZT, Zhang ZY,et al. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. Int J Gynecol Cancer,2003 ,13(4):419-27
240 Chatzigeorgiou K, Economou S, Chrysafis G,et al. Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol,2003 ,125(10):424-429
241 Merideth MA, Cliby WA, Keeney GL,et al. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol,2003 ,89(1):16-21
242付晨薇，沈铿，吴鸣，等.复发性卵巢上皮性癌再次手术的临床评价. 中华妇产科杂志.2003,38(11);661-663
243 Bristow RE, Gossett DR, Shook DR,et al. Recurrent micropapillary serous ovarian carcinoma. Cancer. 2002 , 15;95(4):791-800
244 Tay EH, Grant PT, Gebski V,et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol,2002 ,99(6):1008-1013
245 Zang R, Zhang Z, Cai S. Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer. Zhonghua Zhong Liu Za Zhi,2002 ,24(2):194-196
246 Zang RY, Zhang ZY, Li ZT,et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol,2000,26(8):798-804
247 Zylberberg B, Dormont D, Janklewicz S,et al. Secondary cytoreductions in the treatment of ovarian cancers. Gynecol Obstet Fertil,2000 ,28(2):127-136
248 Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 2000, 88(1):144-153
249 Cormio G, di Vagno G, Cazzolla A,et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol,1999,86(2):185-188
250 Gemignani ML, Chi DS, Gurin CC,et al. Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol,1999 ,72(3):407-410
251 Eng-Hseon T, Peter TG,Val G,et al.Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Obstetrics & Gynecology,2002,90(6):1008-1012
252 Carlo S,Angelo G,Antonimo G.Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.Gynecologic Oncology,2001,83:504-512
253 Cormio G,di Vagno G,Cazzolla A, et al. Surgical treatment of recurrent ovarian cancer:report of 21 cases and a review of the literature .Eur J Obstet Gynecol Reprod Biol,1999,86(2):185-188
Munkarah A, Levenback C, Wolf JK, et al.Secondary cytoreductive surgery for localized
intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol,2001,81(2):237-241
Eisenkop SM,Friedman RL,Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 2000, 88(1):144-153
Tay EH,Grant PT,Gebski V,Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Obstet Gynecol,2002,99(6):1008-1013
Eisenkop SM,Friedman RL,Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer,2000,88(1):144-153
258 Parmar MK, Ledermann JA, Colombo N,et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003 ,361(9375):2099-2106
259 Dizon DS, Dupont J, Anderson S,et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol, 2003 ,91(3):584-590
260 Thigpen JT, Blessing JA, Olt G,et al. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol, 2003 ,90(3):581-586
261 Gronlund B, Hansen HH, Hogdall C,et al. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer,2002 ,95(8):1656-1662
262 Balbi G, Di Prisco L, Musone R,et al. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma. Eur J Gynaecol Oncol, 2002,23(4):347-349
263 Gershenson DM. Irinotecan in epithelial ovarian cancer. Oncology (Huntingt), 2002 ,16(5 Suppl 5):29-31
264 Lehoczky O, Bagameri A, Lehoczky G,et al. Early results of topotecan therapy in patients with recurrent ovarian cancer. Orv Hetil, 2002,143(16):825-828
265 Dizon DS, Hensley ML, Poynor EA,et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol,
2002 ,20(5):1238-1247
266 Benedetti Panici P, Greggi S, Amoroso M,et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int J Gynecol Cancer, 2001,11(6):438-444
267 Clarke-Pearson DL, Van Le L, Iveson T,et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol, 2001 ,19(19):3967-3975
268 Hensley ML, Hoppe B, Leon L,et al. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecol Oncol, 2001 ,82(3):464-469
269 Adachi S, Ogasawara T, Ito K,et al. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer. Oncol Rep, 2001 ,8(2):285-288
270 Morgan RJ Jr, Braly P, Leong L,et al. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. Gynecol Oncol,2000 ,77(3):433-438
271 Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs, 1999,58 Suppl 3:43-49
272 Fung MF, Johnston ME, Eisenhauer EA, et al. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials. Eur J Gynaecol Oncol, 2002,23(2):104-110
273 Gore ME, Atkinson RJ, Thomas H, Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. Eur J Cancer, 2002,38 (Suppl 8):7-12
274 Blackledge G. Cancer drugs: the next 10 years. Eur J Cancer ,2003 , 39(3):273-276
275 Williams CJ,Simera I.Tamoxifen for relapse of ovarian cancer.Cochrane Database syst Rev,2003,(2):CD001034
Cynthia DO,Rosemary DC,Sharan LC,et al.Survival of California women with epithelial ovarian cancer,1994-1996:a population-based study.Gynecol Oncol,2003,91:608-615
3 沈铿，郎景和.妇科肿瘤面临的问题和挑战.第一版.北京：人民卫生出版社,2002,89
4 Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol, 2003, 21(6):1180-1189
Hauptmann S, Denkert C, Koch I, et al. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol ,2002 ,33(6):632-641
Bichel P.A new histological grading index in ovarian carcinoma. Int J Gynecol PATHOL,1989,8:147
Vinokurov VL, Irzhanov SI, Zel'dovich DR, et al. Patterns in the metastasis of malignant ovarian tumors based on autopsy data .Vopr Onkol,1985,31(12):62-69
Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev, 2003 ,22(4):465-472
Terauchi F, Tanabe K, Tenmyo M, et al. Clinical study on total omentumectomy for ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi, 1995 ,47(1):14-18
Sakai K, Kamura T, Hirakawa T,et al. Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer. Gynecol Oncol, 1997 ,65(1):164-8
Vinokurov VL, Kolosov AE, Nechaeva ID，et al. Characteristics of the metastasis of endometrioid cancer of the ovaries into the greater omentum. Vopr Onkol, 1979,25(3):20-24
Vinokurov VL, Kolosov AE. metastasis to the greater omentum Vopr Onkol, 1980,26(2):30-34
Funt SA, Hricak H. Ovarian Malignancies. Topics in Magnetic Resonance Imaging. Magnetic Resonance Imaging in Gynecologic Disease, 2003,14(4):329-337
Wu PC, Lang JH, Huang TL, et al. Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer. Clin Obstet Gynecol,1989,3:143
Di Te F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at
the end of the second millennium. Int J gynecol Cancer,2000,10(6):435-442
Brughardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaotic lymph node involvement in ovarian cancer. Gynecol Oncol,1997,40(2):103-106
Di Re F,Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer. prognostic significance of node metastases. Gynecol Oncol,1996,62:360-365
Parazzini F, Valsecchi G, Bolis G, et al. Pelvic and paraotic lymph nodal status in advanced ovarian cancer and survival .Gynecol Oncol,1999,74(1):7-11
Cormio G, Rossi C, Cazzolla A,et al. Distant metastases in ovarian carcinoma.Int J Gynecol Cancer.,2003 ,13(2):125-129
Muggia FM, Braley PS, Brady MF, et al. Phase Ⅲ randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or IV ovarian cancer: A gynecologic oncology group study.J Clin Oncol 2000,18(1):106-115
du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst,2003,95(17):1320-1329
吴令英，张蓉，章文华.紫杉醇联合铂类周疗与月疗治疗卵巢上皮性前瞻性研究.肿瘤学杂志,2002，8(4):190
23 Sehouli J, Stengel D, Elling D, et al. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.Gynecol Oncol, 2002 ,85(2):321-326
24 Seidman AD, Hudis CA, Albanel J, et al. Dose—dense therapy with weekly 1—hour paclitaxel infusions in the treatment of metastatic breast cancer .J Clin Oncol,1998,16:3353—3361
25 Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol, 2003 ,90(3 Pt 2):8-15
26 Copeland LJ, Bookman M, Trimble E,et al. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol, 2003 ,90(2 Pt 2):1-7
27 Bristow TE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol,2002,20:1248-1259
28 Hogberg T; Glimelius B; Nygren P,et al.A systematic overview of chemotherapy effects in ovarian cancer.Acta Oncol, 2001,40(2-3):340-360
29 Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003,3(7):502-516
Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol, 2003 , 90(3 Pt 2):39-44
Hogdall EV, Christensen L, Kjaer SK,et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer, 2003 , 98(1):66-73
Tanner B, Kreutz E, Weikel W,et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol, 1996 ,62(2):268-77
33 Rose SL, Goodheart MJ, DeYoung BR, et al. p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res, 2003, 9(3):1028-1032
34 Scambia G, Masciullo V, Benedetti Panici P, et al.Prognostic significance of ras/p21 alterations in human ovarian cancer. Br J Cancer, 1997,75(10):1547-1553
35 Schuyer M, van der Burg ME, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.Br J Cancer, 2001 ,85(9):1359-1367
36 Kupryjanczyk J, Szymanska T, Madry R, et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer, 2003,88(6):848-854
37 Morita K, Ono Y, Fukui H, et al. Incidence of p53 and K-ras alteration in ovarian mucinous and serous tumors. Pathol Int,2000,50(3):219-223
38 Havrilesky L, Darcy M, Hamdan H, et al.Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol, 2003, 21(20):3814-3825
39 Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat, 2003,21(3):285-291
Gadducci A, Cosio S, Muraca S, et al. Molecular mechanisms of apoptosis and
chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol, 2002,23(5):390-396
41 Okada K,Urano T,Goi T,et al.Isolation of human nm23 genomens and analysis of loss of heterozygosity in primary colorectal carcinomas using a specifi genomic probe,Cancer Res,1994,54:3879
42 Galani E, Sgouros J, Petropoulou C,et al. Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res, 2002 ,22(4):2275-2280
43 Tomic S, Ilic Forko J, Babic D,et al. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Croat Med J, 2003 , 44(4):429-434
44 Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol, 2000 ,19(1):3-10
45 Tanake K. Molecular biology of ovarian cancer Gan To Kagaku Ryoho, 1999, 26(14): 2162-2167
46 Reedy M, Gallion H, Fowler JM, et al.Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol, 2002 ,85(2):255-259
47 O'Rourke J, Mahon SM. A comprehensive look at the early detection of ovarian cancer. Clin J Oncol Nurs, 2003 ,7(1):41-47
48 Ivanov S, Ivanov S. Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factorAkush Ginekol (Sofiia),2003,42(3):16-19
49 Nyvang GB,Mogensen O,Bichel P,et al.Combined prognostic importance of CA125, histopathologic grade and DNA-index in advanced ovarian cancer.Eur J Gynaecol Oncol,2000,21(6):569-572
50 Zakrzewska I. CA-125 antigen. Postepy Hig Med Dosw,2002,56(1):29-38
51 Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist, 2002,7 Suppl 5:20-28
52 Yancopoulos GD, Davis S, Gale NW, et al. Vascular specific growth factors and blood vessel formation. Nature ,2000,407:242–248
53 Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol, 1999,237:41–57
54 Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest, 1996,74:1105–1115
55 Alvarez AA, Krigman HR, Whitaker RS, et al.The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res, 1999, 5:587-591
56 Wong Te Fong LF, Gammell SJ, Bamberger ES, et al. Quantification of VEGF-A and PD-ECGF/TP in normal, benign and malignant ovarian lesions. Rev Oncol 2002,4(suppl 1):122
57 Siddiqui GK, Wong Te Fong LF, Rolfe KJ, et al. The expression of VEGF-A in metastatic epithelian ovarian cancer is of prognostic significance. Br J Obstet Gynaecol, 2001,108:549
58 Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol, 2002 ,55(6):348-359
59 Suzuki M, Kobayashi H, Ohwada M, et al. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors in the ovary.Gynecol Oncol,1998,68:35-37
60 Toy EP, Chambers JT, Kacinski BM,et al. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol, 2001, 80(2):194-200
61 Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res, 2003, 63(6):1413-1419
62 Le T, Adolph A, Krepart GV,et al.The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.Gynecol Oncol, 2002,85(2):351-355
63 Rubin SC, Markman M. Surgical staging of ovarian cancer. Bristol-Myers Oncology Division Medical Education Services. Bristol-Myers Squibb Company, Princeton, New Jersey, 1992
64 Takec I. Role of appendectomy in predicting lymph node metastases in patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 2000,88(2):159-163
65 Bese T,Kosebay D,Kaleli S,etal.Appendectomy in the surgical staging of ovarian carcinoma. Int J Gynaecol Obstet,1996,53(3):249-252
66 Fawzi HW, Robertshaw JK, Bolger BS, et al.Role of appendicectomy in the surgical management of ovarian cancer.Eur J Gynaecol Oncol, 1997,18(1):34-35
67 Kecmanovic DM, Pavlov MJ, Kovacevic PA, et al. Cytoreductive surgery for ovarian cancer. Eur J Surg Oncol,2003 ,29(4):315-320
68 Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother, 2001 ,2(1):109-124
69 Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium. Int J Gynecol Cancer, 2000 ,10(6):435-442
70 Yokoyama Y,Sakamoto T,Sato S,etal.Evaluation of cytoruductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.Eur J Gynaecol Oncol,1999,20(5-6):132-366
Faught W, Le T, Fung Kee Fung M, et al. Early ovarian cancer: what is the staging impact of retroperitoneal node sampling? J Obstet Gynaecol Can，2003 , 25(1):18-21
Burghardt E,Pickel H,Lahousen M,et al.Pelvic lymphadenectomy in operative treatment of ovarian cancer.Am J Obstet Gynecol,1986,155(2):315-319
Kikkawa F,Ishikawa H,Tamakoshi K,et al.Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer.J Surg Oncol,1995,60(4):227-231
Saygili U, Guclu S, Uslu T,et al. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage Ⅲ ovarian carcinoma? A DEGOG* Study. J Surg Oncol, 2002 ,81(3):132-137
Kigawa J,Minagawa Y,Itamochi H,et al.Retroperitoneal lymphadenectomy,including the para-aortic nodes in patients in patients with stage Ⅲ ovarian cancer.Am J Clin Oncol,1994,17(3):230-233
76 Morice P, Camatte S, Wickart-Poque F,et al. Conservative management of malignant and borderline ovarian tumor.Bull Cancer,2002 , 89(12):1019-1026
77 Morice P,Wicart-Poque F,Rey A,et al.Results of conservative treatment in epithelial ovarian carcinoma.Cancer,2001,92(9):2412-2418
Plante M.Fertility preservation in the management of gynecologic cancers .Curr Opin Oncol,2000,12:495-497
Zanetta G,Chiari S,Rota S,et al.Conservative surgery for stage I ovarian canrcinoma in women of childberaring age.Br J Obstet Gynaecal,1997,104(9):1030-1035
80 Morice P, Camatte S, Wicart-Poque F ,et al.Results of conservative management of epithelial malignant and borderline ovarian tumours.Hum Reprod Update.,2003,9(2):185-192
81 Ayhan A, Celik H, Taskiran C, et al.Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.Eur J Gynaecol Oncol, 2003,24(3-4):223-232
82 Suzuki M , Tsukagoshi S, Ohwada M et al.A patient with brain metastasis from ovarian cancer who showed complete remission after multidisciplinary treatment. Gynecol Oncol ,1999,74(3):483-486
83 Onnis A ,Marchetti M, Padovan P et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol,1996,17:393-396
84 Munkarrah AR, Hallum AV, Morris M et al.Prognostic significance of residual disease in patients with stage Ⅳ epithelial ovarithelial ovarian cancer. Gynecol Oncol, 1997,64:13-7
85 Dauplat J, Bouedec G, Pomel C,et al.Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol ,2000,19(1):42-48
86 Tingulstad S, Skjeldestad FE, Hagen B.The effect of centralization of primary surgery on survival in ovarian cancer patients.Obstet Gynecol, 2003 ,102(3):499-505
87 Hamid D,Rohr S,Baldauf JJ,et al.Interest in intestinal resection for treatment of advanced ovarian cancer.Ann Chir,2002,127(1):40-47
88 Balbi GC,Compagna R,Musone R, et al.Cytoreductive surgery in patients with stage IV ovarian carcinoma.Mineva Gynecol,2001, 53[Suppl 1]:105-109
89 Todo Y, Sakuragi N, Oikawa M, et al. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.Int J Clin Oncol, 2003 ,8(2):90-96
90 Friedman TL, Eisenkop SM, Wang HJ. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol,1997,67(1):88-94
91 Baker VV. Treatment Options for Ovarian Cancer. Clinical Obstetrics & Gynecology, 2001 ,44(3):522-530
92 Ott HW, Illmensee K, Zeimet A, et al.The evaluation of the second-look operation of patients with ovarian carcinoma and tubal carcinoma by means of a retrospective comparison study.Gynakol Geburtshilfliche Rundsch, 2002,42(4):217-224
93 Eisenkop SM,Friedman RL,Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer,2000,88(1):144-153
94 Munkarah A, Levenback C, Wolf JK, et al.Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol,2001,81(2):237-241
95 Federica B, Monica C, Nicola R, et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res, 1999, 5: 1837-1842
96 Kazuya K, Masashi T, Tomoyuki K, et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res ,1999, 5: 2526-2531
97 Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist, 2002,7(5):20-28
98 Salom E, Almeida Z, Mirhashemi R. Management of recurrent ovarian cancer: evidence-based decisions. Current Opinion in Oncology, 2002,14(5):519-527
99 Bristow RE. Surgical standards in the management of ovarian cancer. Current Opinion in Oncology, 2000, 12(5):474-480
100 Udarah A, Levenback C, Wolf J, et al. Secondary cytoreductive surgery for intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol, 2001, 81:237–241
101 kuhn W, Schmalfeldt B, Pache L, et al. Disease-adapted relapse therapy for ovarian cancer: results of a prospective study. Int J Oncol, 1998, 13:57–63
102 Mundarah A, Levenback C, Wolf J, et al. Secondary cytoreductive surgery for intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol, 2001, 81:237–241
103 Eisenkop SM, Friedman RL, Spirtos NM.The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer, 2000, 88(1):144-153
104 Tay EH, Grant PT, Gebski V, et al.Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Obstet Gynecol,2002 , 99(6):1008-1113
105 Gadduci S,Iacconi P,Cosio S,et l.Complete salvage surgical cytoreduction improves further survivial of patients with late recurrent ovarian cancer.Gynecol oncol,2000,79:344-349
106 Kuhn W,Schmalfeldt B,Pache L,et al.Disease-adapted relapse therapy for ovarian cancer:results of a prospective study .Int J Oncol,1998,13(1):57-63
107 McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with
paclitaxel and cisplatin in patients with stage Ⅲ and stage IV ovarian cancer. N Engl J Med ,1996, 334:1–6
108 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase Ⅲ randomized trial in patients with suboptimal stage Ⅲ/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol ,1996,23(12):40-47
109 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage Ⅲ and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol, 1997,24(2):S2-13-S2-16
110 Schink JC. Current initial therapy of stage Ⅲ and IV ovarian cancer: challenges for managed care. Semin Oncol 1999, 26:2–7
111 Piccart MJ,Bertelsen K,James K,et al.Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer :three-year results.J Natl Cancer Inst,2000,92(9):699-708
112 Fleming GF, Toth BJ,Baker SD,et al.Phase I trial of paclitaxel and etoposide for recurrent ovarian cancer: a Gynecologic Oncology GroupStudy.Am J Clin,2000,23(6):609-613
113 Bristow RE, Tomacruz RS, Amstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002, 20:1248-1259
114 Pecorelli S, Odicino F, Favalli G. Ovarian cancer: best timing and applications of debulking surgery. Ann Oncol ,2000, 11 (Suppl 3):141-144
115 Amikura T, Aoki Y, Kase H,et al. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy.Int J Clin Oncol, 2002 , 7(1):45-50
116 Eltabbakh GH,Piver MS,Hempling RE,et al.Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovrian cancer.Gynecol Oncol,1998,71(2):190-195
117 Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. Cancer ,2001, 91:2239-2334
118 Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage ⅢC ovarian carcinoma. Cancer, 2001, 92:2585-2591
119 Eisenkop SM, Spirtos NM, Friedman RL. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol ,1999, 74: 311-313
121 Kayikciog Lu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer, 2001, 11:466-470
122 Markman M: Intraperitoneal therapy of ovarian cancer. Semin Oncol ,1998, 25:356–360
123 Friberg G, Fleming G.Intraperitoneal chemotherapy for ovarian cancer. Curr Oncol Rep, 2003,5(6):447-453
124 Rossi CR, Mocellin S, Pilati P, et al.Pharmacokinetics of intraperitoneal cisplatin and doxorubicin.Surg Oncol Clin N Am, 2003 ,12(3):781-794
117 Gurkan Zorlu C, Eylem Seker Ari P. Hyperthermia in gynecologic cancers.Eur J Gynaecol Oncol, 2003,24(3-4):282-286
125 Fujiwara K, Sakuragi N, Suzuki S, First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.Gynecol Oncol, 2003 ,90(3):637-643
126 Makhija, Sharmila AS, Paul BB, et al. Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Current Opinion in Obstetrics & Gynecology, 1999,11(1):23-27
127 Khabele D, Runowicz CD, Fields AL, Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies.Gynecol Oncol, 2003 ,89(3):420-423
128 Breidenbach M, Rein DT , Mallmann Peter ,et al. Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anti-Cancer Drugs, 2002, 13(2):173-176
129 Piccart M. J, Lamb H, Vermorken J B.. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Annals of Oncology, 2001,12(9):1195-1203
130 Dancey J, Zee B, Osoba D, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer
Institute of Canada Clinical Trials Group. Qual Life Res, 1997, 6:151-158
131 Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol, 1999, 10 (Suppl 1): 87-92
132 Giaccone G. Clinical perspectives on platinum resistance. Drugs ,2000, 59 (Suppl 4): 9-17
133 Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist, 2000, 5: 26-35
134 Aravantinos G, Bafaloukos D, Fountzilas G, Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.Ann Oncol, 2003 ,14(7):1094-1199
135 Herzog TJ, Holloway RW, Stuart GC. Workshop: options for therapy in ovarian cancer.Gynecol Oncol, 2003 ,90(3 Pt 2): 45-50
136 Berek JS,Bertelsen K,du Bois A,et al.Advanced epithelial ovarian cancer:1998 consensus statements.Ann Oncol,1999,10(Suppl 1):87-92
137 Deppe G, Baumann P. Advances in ovarian cancer chemotherapy. Current Opinion in Oncology, 2000,12(5):481-491
138 Morris RT. Weekly topotecan in the management of ovarian cancer.Gynecol Oncol, 2003 ,90(3 Pt 2): 34-38
139 Miller DS, Blessing JA, Lentz SS, Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.Cancer, 2003 ，98(8):1664-1669
140 Fruscella E, Gallo D, Ferrandina G, Gemcitabine: current role and future options in the treatment of ovarian cancer.Crit Rev Oncol Hematol,2003 ,48(1):81-88
141 Rose PG, Blessing JA, Ball HG, et al.A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol, 2003,88(2):130-135
142 Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene–glycol coated liposomes. Cancer Res, 1994, 54:987–992
143 Tambaro R, Greggi S, Iaffaioli R,et al. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. Annals of Oncology, 2003 ,14(9):1406-1411
144 Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol ,2000,78:369–372
145 D'Agostino G, Ferrandina G, Ludovisi M, Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.Br J Cancer, 2003 ,89(7):1180-1184
146 Rose PG, Blessing JA, Mayer AR. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian cancer. A Gynecologic Oncology Group study. J Clin Oncol, 1998, 16: 405–10
147 Ostanin AA, Chernykh HR, Leplina OY, IL-2-Activated Killer Cells and Native Cytokines in Treatment of Patients with Advanced Cancer.Russ J Immunol, 1997 ,2(3-4):167-176
148 Lum LG,Lefever AV,Treisman JS,et al.Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial.J Immunother, 2001 ,24(5):408-419
149 Marme A, Strauss G, Bastert G,et al. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma.Int J Cancer, 2002 ,101(2):183-189
150 Melichar B, Savary CA, Patenia R, et al. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma.Int J Gynecol Cancer, 2003 ,13(4):435-443
151 Berek JS,Stonebraker B,Lentz SS,et al.Intraperitoneal alpha-interferon in residual ovarian carcinoma:a phase II gynecologic oncology group study .Gynecol Oncol,1999,75:10-14
152 Santin AD，Ioli GR，Hiserodt JC，et al．Development and charac＿terization of an IL－4－secreting human ovarian carcinoma cell line．Gynecol Oncol，1995，58：230
153 D＇Incan C，Sanches R，Kuiper M，et al．Gamma－interferon genetransfer as a therapeutic strategy for ovarian cancer．Adv Exp Med Biol，1998，451：349
154 Bernhard H, Salazar L, Schiffman K,et al. Vaccination against the HER-2/neu oncogenic protein.Endocr Relat Cancer, 2002,9(1):33-44
155 Linehan DC, Peoples GE, Hess DT, et al.In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. Surg Oncol, 1995,4:41-49
156 Brossart P. Dendritic cells in vaccination therapies of malignant diseases.Transfus Apheresis
Sci, 2002 ,27(2):183-186
157 Reinartz S,Boerner H,Koehler S,et al.Evaluation of immunological responses in patients with ovarian cancer the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report .Hybridom,1999,18:41-45
158 Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ,et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.Oncogene, 2003 ,22(3):370-380
159 Grove JI, Lovering AL, Guise C,et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.Cancer Res, 2003,63(17):5532-5537
160 Alvarez RD, Barnes MN, Gomez-Navarro J,et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.Clin Cancer Res, 2000,6(8):3081-3087
161 Wen SF, Mahavni V, Quijano E,et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.Cancer Gene Ther, 2003 ,10(3):224-238
162 Buller RE, Runnebaum IB, Karlan BY, et al.A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.Cancer Gene Ther,2002,9(7):553-566
163 Saga Y, Mizukami H, Takei Y,et al. Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression.Int J Oncol, 2003 ,23(4):1109-1113
164 Qian HN, Liu GZ, Cao SJ,et al. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes.Int J Gynecol Cancer, 2002 ,12(1):80-85
165 Schiedlmeier B, Schilz AJ, Kuhlcke K,et al. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice.Hum Gene Ther, 2002 ,13(2):233-242
166 Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer.Gan To Kagaku Ryoho, 2003 ,30(4):468-477
167 Kohno T, Mizukami H, Suzuki M,et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.Cancer Res, 2003 ,63(16):5091-5094
168 Mu J, Abe Y, Tsutsui T,et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Jpn J Cancer Res, 1996 ,87(9):963-971
169 Saul HM, Sedlacek TV, Heller PB,et al. Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer.J Am Osteopath Assoc, 1996 ,96(12):727-732
170 Condra KS, Mendenhall WM, Morgan LS,et al. Adjuvant 32P in the treatment of ovarian carcinoma.Radiat Oncol Investig, 1997,5(6):300-304
171 Einhorn N, Trope C, Ridderheim M,et al. A systematic overview of radiation therapy effects in ovarian cancer.Acta Oncol,2003,42(5-6):562-566
172 Firat S, Murray K, Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.Int J Radiat Oncol Biol Phys, 2003 ,57(1):201-207
173 Randall ME, Barrett RJ, Spirtos NM,et al. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys, 1996 ,34(1):139-147
174 Pickel H, Lahousen M, Petru, et al.Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer.Gynecol Oncol,1999,72(2):215-219
175 Hepp R, Baeza MR, Olfos P,et al. Adjuvant whole abdominal radiotherapy in epithelial cancer of the ovary.Int J Radiat Oncol Biol Phys, 2002, 53(2):360-365
176 Goldberg H, Stein ME, Steiner M,et al. Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up.Tumori, 2001 ,87(4):248-251
177 MacGibbon A, Bucci J, MacLeod C,et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma.Gynecol Oncol, 1999 ,75(1):62-67
178 Condra KS, Mendenhall WM, Morgan LS,et al. Condra KS, Mendenhall WM, Morgan LS, Marcus RB, Jr. Consolidative 32P after second-look laparotomy for ovarian carcinoma. Radiation Oncology Investigations, 1998;6(2): 97-102
179 Petera J, Spacek J, Odrazka K. Radiotherapy in the treatment of ovarian epithelial
carcinoma.Ceska Gynekol, 2003,68(4):264-269
180 Fujiwara K, Suzuki S, Yoden E,et al. Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.Int J Gynecol Cancer, 2002 ,12(3):250-256
181 Corn BW, Mehta MP, Buatti JM, et al. Stereotactic Irradiation: potential new treatment method for brain metastases resulting from ovarian cancer. Am J Clin Oncol, 1999,22(2):143-146
182 Fyles AW, Thomas GM, Pintilie M, et al. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II and Ⅲ ovarian cancer .Int J Radiat Oncol Biol Phys,1998,41(3):543-549
183 Quetin P, Marchal C, Hoffstetter S,et al. Tolerance and role of irradiation in the treatment of epithelial cancer of the ovary.Cancer Radiother, 1998,2(4):366-374
184 Wolf JK, Mullen J, Eifel PJ,et al. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary.Gynecol Oncol, 1999, 73(1):35-41
185 Sackett DL, Straus SE, Richardson WS, et al. Evidence-based medicine: How to practice and teach evidence-based medicine. London: Churchill Livingstone,2000 :1-19
186 Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst, 2003,95(17):1276-1299
187 Salom E, Almeida Z, Mirhashemi Rv. Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol,2002 ,14(5):519-527
188 David AG, David A. The U.S. Preventive services task force: putting evidence-based medicine to work. Clinical Obstet Gynecol,1998,41(2):332-342
189 Gray RE, Chart P, Carroll JC, et al. Family physicians’ perspectives on ovarian cancer. Cancer Prev Control,1999,3(1):61-67
190 Lefebvre G, Allaire C, Jeffrey J. SOGC clinical guidelines.Hysterectomy. J Obstet Gynaecol Can,2002,24(1):37-61
191 Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.J Natl Cancer Inst, 2002,94:497-504
192 David MP.Hormone replacement therapy with continuous progestins was not associated with
an increased risk of ovarian cancer. Evidence-based Obstetrics and Gynecology,2002,4:150-151
193 Teede HJ. Hormone replacement therapy and the prevention of cardiovascular disease. Human Reproduction Update, 2002，8(3):201-215
194 Modan B, Hartge P, Hirsh-Yechezkel G,et al.Oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA1 mutation .N Engl J Mde,2001,345:235-240
195 Bengt G, Jonas B, Lars B, et al.The Swedish council on technology assessment in health care(SBU) systematic overview of chemotherapy effects in some major tumour types-summary and conclusion.Acta Oncol,2001,40:135-154
196 Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, Ⅲ, or IV epithelial ovarian cancer. Gynecol Oncol,2002, 85(1):71-80
197 Williams C, Collingwood M, Simera, et al. Short versus long duration infusions of paclitaxel for any adenocarcinoma(Cochrane Review). Oxford .Cochrane Library.Issue 2 .2003
198 Vermorken JB. Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer, 2001,11 suppl1:73-76
199 Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer (Cochrane Methodology Review). Oxford .Cochrane Library.Issue 4 .2003
200 Trope C ,Paulsen T ,baekelandt M ,et al. Controversies in surgical treatment of advanced ovarian cancer .Tidsskr Nor Laegeforen,2000,120(7):824-830
201 Cantu M, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.J Clin Oncol, 2002,20:1232-1237
202 Gordon AN, Fleagle JT,Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase Ⅲ study of pegylated liposmal doxorubicin versus topotecan. J Clin Oncol,2001,19(14):3312-3322
203 Willian CJ,Simera I.Tamoxifen for relapse of ovarian cancer(Cochran Review). Oxford. Cochrane Library.Issue 4 .2003
van T M, Furlan A, Bombardier C ,et al. the Editorial Board of the Cochrane Collaboration Back Review Group. Updated Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group. Spine, 2003 ,28(12):1290-1299
Clark TG, Stewart ME, Altman DG,et al.A prognostic model for ovarian cancer.Br J Cancer ,2001,85:944-952
Brun JL,Feyler A,Chene G,et al.Long term results and prognostic factors in patients with epithelial ovarian cancer.Gynecol Oncol,2000,78:21-27
Bristow TE,Tomacruz TS,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis.J Clin Oncol,2002,20:1248-1259
Scarabelli C, Gallo A, Franceschi S et al.Primary Cytoreductive surgery with rectosigmoid colon for patients with advanced epithelial ovarian carcinoma. Cancer ,2000,88(2):389-97
熊宙芳，王泽华，王世宣.卵巢上皮性癌的腹膜后淋巴结切除对预后的影响.中华妇产科杂志，2003，38(2):77
Poveda A.Ovarian cancer treatment: what is new. Int J Gynecol Cancer,2003,13 (Suppl 2):241-250
Yokoyama Y,Sakamoto T,Sato S,et al. Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.Eur J Gynaecol Oncol, 1999, 20(5-6):361-366
Allen DG, Coulter J. Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease.Aust NZJ Obstet Gynaecol ,1999 ,39(4):420-424
Tien Le, Allyson Adolph, G.V. Krepart, et al.The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.Gynecol Oncol,2002,85:351-355
王荣业.84例晚期卵巢上皮癌的综合治疗.浙江肿瘤.2000,6(2):75-77
熊宙芳，王泽华，王世宣.卵巢上皮性癌的腹膜后淋巴结切除对预后的影响.中华妇产 科杂志.2003，38（2）：77-80
Scott M.Eisenkop, Nick M.Spirtos, Richard L.Friedman, et al. Relative influences of tumor
volume before surgery and the advanced ovarian cancer:a prospective study.2003,90:390-396
Ho CM, Chien TY, Shih BY,et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol, 2003,88(3):394-399
Moher D, Dook DJ, Eastwood S,et al. Improving the quality of reports of Meta-analyses of randomized controlled trials: the QUOROM statement. The Lancer,1999, 354(27):1896-1900
Jadad AR, Moore RA, Carroll D,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996 ,17(1):1-12
Moher D，Pham B，Jones A， et al．Does quality of reports of randomised trials affect estimates of intervention efficacy reported in Metaanalyses［J］．Lancet ,1998, 352:609-613
Clarke M，Oxman AD，editors．Cochrane Reviewers Handbook 4.0; Section 6．In:The Cochrane Library［database on CDROM］．The Cochrane Collaboration．Oxford:Update Software;2000，issue 1
Schula KF，Chalmers I，Hayes R，Altman D．Empiricalevidence of bias［J］．JAMA,1995, 273（5）: 408-412
Vickers A，Goyal N，Harland R，Rees R．De certain countries preduce only positive results? A systematic review of controlled trials［J］．Control Clin Trials ,1998, 19:159-166
Egger M，Devey Smith G，Schneider M，et al．Bias in Meta-analysis detected by a simple graphical test［J］．BwJ ,1997, 315:629-634
郎景和.I期卵巢癌的淋巴结转移，中华妇产科杂志，1992,27:338
Morice P, Joulie F, Rey A,et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol, 2004;25(2):169-174
Fabio FP，Giorgio B, Paolo G,et al. Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival.Gynecol Oncol, 1999,74:7-11
Baiocchi G, Grosso G, di Re E, et al. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Gynecol Oncol, 1998,69:151
Gadducci A, Sartori E, Maggino T ,et al. analysis of failures after negative second-look in patients with advanced ovarian cancer; an Italian multicenter study. Gynecol Oncol, 1998, 68:150
230 Peter E.Schwartz.Neoadjuvant chemotherapy for the management of ovarian cancer.Best Practice & Research Clinical Obstetrics and Gynaecology,2002,16(4):585-596
231孙延慰，祝亚平，李双弟，等.上皮性卵巢癌的综合治疗及疗效分析.上海医学.2001,24(8):487-489
232 Kayikciog Lu F,Kose MF,Boran N,et al.Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma.Int J Gynecol Cancer,2001,11:466-470
233 Fanfani F, Ferrandina G, Corrado G,et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage Ⅲc ovarian cancer patients. Oncology, 2003,65(4):316-322
234 Morice P, Brehier-Ollive D, Rey A,et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol, 2003,14(1):74-77
235 Kuhn W, Rutke S, Spather K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage Ⅲc ovarian carcinoma. Cancer, 2001, 92:2585
236 Ansquer Y, Leblanc E, Clough K, et al.Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer, 2001(81):2329-2334
237 Schwartz PE, Rutherford TJ, Chambers JT,et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol,1999,72:93-99
238 Vergote I,Dewever I,Tjalma W,et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology ,1998(71):431-436
239 Zang RY, Li ZT, Zhang ZY,et al. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. Int J Gynecol Cancer,2003 ,13(4):419-27
240 Chatzigeorgiou K, Economou S, Chrysafis G,et al. Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol,2003 ,125(10):424-429
241 Merideth MA, Cliby WA, Keeney GL,et al. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol,2003 ,89(1):16-21
242付晨薇，沈铿，吴鸣，等.复发性卵巢上皮性癌再次手术的临床评价. 中华妇产科杂志.2003,38(11);661-663
243 Bristow RE, Gossett DR, Shook DR,et al. Recurrent micropapillary serous ovarian carcinoma. Cancer. 2002 , 15;95(4):791-800
244 Tay EH, Grant PT, Gebski V,et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol,2002 ,99(6):1008-1013
245 Zang R, Zhang Z, Cai S. Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer. Zhonghua Zhong Liu Za Zhi,2002 ,24(2):194-196
246 Zang RY, Zhang ZY, Li ZT,et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol,2000,26(8):798-804
247 Zylberberg B, Dormont D, Janklewicz S,et al. Secondary cytoreductions in the treatment of ovarian cancers. Gynecol Obstet Fertil,2000 ,28(2):127-136
248 Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 2000, 88(1):144-153
249 Cormio G, di Vagno G, Cazzolla A,et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol,1999,86(2):185-188
250 Gemignani ML, Chi DS, Gurin CC,et al. Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol,1999 ,72(3):407-410
251 Eng-Hseon T, Peter TG,Val G,et al.Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Obstetrics & Gynecology,2002,90(6):1008-1012
252 Carlo S,Angelo G,Antonimo G.Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.Gynecologic Oncology,2001,83:504-512
253 Cormio G,di Vagno G,Cazzolla A, et al. Surgical treatment of recurrent ovarian cancer:report of 21 cases and a review of the literature .Eur J Obstet Gynecol Reprod Biol,1999,86(2):185-188
Munkarah A, Levenback C, Wolf JK, et al.Secondary cytoreductive surgery for localized
intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol,2001,81(2):237-241
Eisenkop SM,Friedman RL,Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 2000, 88(1):144-153
Tay EH,Grant PT,Gebski V,Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Obstet Gynecol,2002,99(6):1008-1013
Eisenkop SM,Friedman RL,Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer,2000,88(1):144-153
258 Parmar MK, Ledermann JA, Colombo N,et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003 ,361(9375):2099-2106
259 Dizon DS, Dupont J, Anderson S,et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol, 2003 ,91(3):584-590
260 Thigpen JT, Blessing JA, Olt G,et al. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol, 2003 ,90(3):581-586
261 Gronlund B, Hansen HH, Hogdall C,et al. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer,2002 ,95(8):1656-1662
262 Balbi G, Di Prisco L, Musone R,et al. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma. Eur J Gynaecol Oncol, 2002,23(4):347-349
263 Gershenson DM. Irinotecan in epithelial ovarian cancer. Oncology (Huntingt), 2002 ,16(5 Suppl 5):29-31
264 Lehoczky O, Bagameri A, Lehoczky G,et al. Early results of topotecan therapy in patients with recurrent ovarian cancer. Orv Hetil, 2002,143(16):825-828
265 Dizon DS, Hensley ML, Poynor EA,et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol,
2002 ,20(5):1238-1247
266 Benedetti Panici P, Greggi S, Amoroso M,et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int J Gynecol Cancer, 2001,11(6):438-444
267 Clarke-Pearson DL, Van Le L, Iveson T,et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol, 2001 ,19(19):3967-3975
268 Hensley ML, Hoppe B, Leon L,et al. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecol Oncol, 2001 ,82(3):464-469
269 Adachi S, Ogasawara T, Ito K,et al. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer. Oncol Rep, 2001 ,8(2):285-288
270 Morgan RJ Jr, Braly P, Leong L,et al. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. Gynecol Oncol,2000 ,77(3):433-438
271 Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs, 1999,58 Suppl 3:43-49
272 Fung MF, Johnston ME, Eisenhauer EA, et al. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials. Eur J Gynaecol Oncol, 2002,23(2):104-110
273 Gore ME, Atkinson RJ, Thomas H, Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. Eur J Cancer, 2002,38 (Suppl 8):7-12
274 Blackledge G. Cancer drugs: the next 10 years. Eur J Cancer ,2003 , 39(3):273-276
275 Williams CJ,Simera I.Tamoxifen for relapse of ovarian cancer.Cochrane Database syst Rev,2003,(2):CD001034